Biofil Chemicals & Pharmaceuticals Limited

Healthcare · Pharmaceuticals & Biotechnology

NSE: BIOFILCHEM BSE: 524396
₹30.38
Sept. 30, 2026 · NSE · nse_bhavcopy

Peers in Pharmaceuticals & Biotechnology

The largest companies in the same industry by market cap. This company ranks #151 of 184. PE, ROE, 1Y return and scores come from the daily/weekly precomputed snapshot.

CompanyMarket cap (₹ Cr)PE (TTM)ROE1Y returnDiv. yieldQualityValuationMomentum
Sun Pharmaceutical Industries Limited 435,863 146.5 13.7% 11.0% — 72 8 30
Divi's Laboratories Limited 246,660 83.9 15.3% 62.7% 0.32% 70 4 51
Torrent Pharmaceuticals Limited 162,454 78.2 12.2% 34.6% 0.79% 56 0 31
Zydus Lifesciences Limited 115,910 33.3 17.3% 17.2% 0.09% 74 24 84
Cipla Limited 108,736 35.4 11.2% -11.0% 0.97% 73 29 62
Laurus Labs Limited 106,969 122.5 17.1% 127.1% — 78 24 53
Mankind Pharma Limited 103,406 47.4 11.7% 2.6% — 68 12 86
Dr. Reddy's Laboratories Limited 102,916 154.7 10.9% -0.9% — 62 33 71
Biofil Chemicals & Pharmaceuticals Limited (this stock) 49 101.3 12.9% -26.8% — 66 37 12

Valuation multiples

Current only. Market cap is the whole company's; sales/EBITDA are trailing-twelve-month standalone; debt and cash come from the latest filed standalone balance sheet (March 31, 2026). EBITDA = PBT + interest + depreciation.

Enterprise value
₹52 Cr
EV / EBITDA
47.7x
EV / Sales
1.53x
Market cap / Sales
1.44x
Earnings yield
0.99%

Quarterly Financials

↑ Positive
Quarterly Revenue

Jun 2026 quarterly revenue is Rs 12 Cr, up 34.0% YoY.

↓ Negative
Quarterly Net Profit

Jun 2026 quarterly net profit is Rs 0 Cr, down 95.5% YoY.

Period endRevenue (₹ Cr)PBT (₹ Cr)Net profit (₹ Cr)Basic EPS
June 30, 2026 12 0 0 ₹0.0700
March 31, 2026 8 0 0 ₹0.1300
Dec. 31, 2025 1 0 0 ₹0.0500
Sept. 30, 2025 14 0 0 ₹0.0500
June 30, 2025 6 3 2 ₹1.4800
March 31, 2025 8 0 0 ₹
Dec. 31, 2024 14 0 0 ₹0.1000
Sept. 30, 2024 2 0 0 ₹0.0100
June 30, 2024 8 0 0 ₹0.1000
March 31, 2024 15 0 0 ₹0.1500
Dec. 31, 2023 5 0 0 ₹0.0600
Sept. 30, 2023 17 0 0 ₹0.0800
June 30, 2023 2 0 0 ₹0.1500

Quarterly income statement (standalone, ₹ Cr)

IndicatorJun 26Mar 26Dec 25Sep 25Jun 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23
Total income (before exceptional items)1281149142816517214
Operating revenue1281146142815517214
Other income0000300000000
Operating expenses1271136142815517213
Operating profit00000000-00000
Operating profit margin1.1%5.8%11.0%0.8%0.1%2.2%5.2%3.6%-0.2%3.8%1.4%17.2%3.0%
Depreciation0000000000000
Interest0000000000000
Exceptional items, gain / (loss)—————————————
Profit before tax0000300000000
Tax0000000000000
Net profit0000200000000
EPS0.070.130.050.051.480.100.010.100.150.060.080.150.07
Net profit (TTM)0333311111111
EPS (TTM)0.301.711.681.641.690.360.320.390.440.360.360.310.29

Total income excludes exceptional items, which are shown on their own row. Trendlyne and Screener fold exceptional items into revenue or other income, so their totals differ from this table by exactly that row.

Annual Financials

Year endedRevenue (₹ Cr)PBT (₹ Cr)Net profit (₹ Cr)
March 31, 2026 28 3 3
March 31, 2025 33 1 1
March 31, 2024 40 1 1
March 31, 2023 30 1 1

Annual income statement (standalone, ₹ Cr; CAGR to the latest year)

IndicatorCAGR 3YCAGR 5YMar 26Mar 25Mar 24Mar 23Mar 22Mar 21Mar 20Mar 19Mar 18Mar 17
Total income (before exceptional items) 1.5% -2.9% 31†—41†30†23†37†30†23†12†—
Operating revenue -1.9% -4.5% 2833403022†36†30†23†12†13†
Other income — — 3†—0†0†0†1†0†0†0†—
Operating expenses — — 28†—39†29†21†34†——11†11†
Operating profit -17.8% -18.2% 1†—1†1†1†2†——1†3†
Operating profit margin — — 2.3%†—2.0%†3.9%†6.0%†4.9%†——7.6%†20.5%†
Depreciation — — 0†—0†0†0†1†——0†0†
Interest — — 0†—0†0†0†0†0†0†0†0†
Exceptional items, gain / (loss) — — 0†—0†0†0†0†0†0†0†-0†
Profit before tax 63.2% 12.4% 31111†2†2†1†1†2†
Tax — — 1†—0†0†0†————0†
Net profit 70.7% 17.5% 31111†1†1†0†0†2†
EPS 80.7% 17.6% 1.71†—0.44†0.29†0.44†0.76†0.81†———

† Derived: the sum of that fiscal year's four quarterly filings (a real annual filing is used wherever one exists). Checked against filed annual figures, the sum lands within 0.5% for about 94% of company-years.

Annual ratios (standalone)

RatioMar 26Mar 25Mar 24Mar 23Mar 22Mar 21Mar 20Mar 19Mar 18Mar 17
Operating margin2.3%†—2.0%†3.9%†6.0%†4.9%†——7.6%†20.5%†
EBIT margin12.2%†—2.3%†2.8%†4.7%†5.8%†5.6%†3.3%†6.0%†18.2%†
PBT margin12.1%2.2%2.2%2.6%4.5%†5.4%†5.2%†2.6%†4.8%†17.0%†
Net margin9.8%1.7%1.8%1.9%3.1%†3.5%†4.3%†2.1%†3.8%†13.3%†
Interest coverage342.54x†—21.80x†19.70x†26.06x†14.60x†13.53x†4.73x†4.91x†14.89x†
Dividend payout——————————
Earnings retention——————————
Current ratio1.73x1.34x————————
Quick ratio1.54x1.23x————————
Debt to equity0.14x0.03x————————
Return on equity12.9%3.0%————————
Return on assets6.5%1.1%————————
Return on capital employed15.6%†—————————
Asset turnover0.66x0.66x————————

Margins and asset turnover use operating revenue (interest earned for banks, excluding other income), not total income. Liquidity, leverage and return ratios need a filed standalone balance sheet, which exists only for recent years; returns use year-end equity/assets. Dividend payout is shown only for companies with a dividend record. † = built from a summed fiscal year.

Revenue Mix

Data unavailable.

Cash Flow

Year endedOperating (₹ Cr)Investing (₹ Cr)Financing (₹ Cr)Capex (₹ Cr)Free Cash Flow (₹ Cr)
March 31, 2026 -1 1 3 0 -1
March 31, 2025 -2 -0 -0 0 -2
March 31, 2024 2 -0 -0 0 2
March 31, 2023 -0 -0 0 0 -0
March 31, 2022 -0 -0 -0 0 -0

Balance Sheet (standalone)

Year endedTotal Assets (₹ Cr)Total Equity (₹ Cr)Reserves (₹ Cr)Borrowings, Current (₹ Cr)Borrowings, Non-current (₹ Cr)Current Assets (₹ Cr)Current Liabilities (₹ Cr)Cash & Equivalents (₹ Cr)Net Block (₹ Cr)Inventory (₹ Cr)
March 31, 2026 43 22 5 3 0 36 21 0 7 4
March 31, 2025 51 19 3 0 0 43 32 0 8 3
March 31, 2024 — — — — — — — — — —
March 31, 2023 — — — — — — — — — —
March 31, 2022 — — — — — — — — — —

Financial charts

Trend charts drawn from the standalone income-statement and ratio tables above (oldest year on the left); a gap means that period has no figure. Annual years marked † in the tables are derived from four quarters.